Delivery Systems: Why Penetration Decides Whether a Claim Holds Up
Delivery Systems: Why Penetration Decides Whether a Claim Holds Up
8
CEO & Founder bei Labtree GmbH
Two products can contain the same active and perform very differently. The reason is delivery. Encapsulation, fragment size and carrier decide whether an ingredient reaches where it is intended to work, and therefore whether a clinical-sounding promise is cosmetically credible.
Themen auf dieser Seite
Das Thema kurz und kompakt
An active is only as good as its delivery: penetration, not the ingredient name, often decides whether a claim is credible.
The delivery system is part of the formulation, so encapsulation, fragment size, carrier and stability have to be designed and tested, not sourced.
In-house development on a real formulation base, with stability validation and 24-hour samples, lets a brand build and prove a delivery system.
The skin barrier exists to keep things out. That makes it a challenge for any active that is intended to work below the surface. An ingredient that cannot get past the barrier in a usable form does little, regardless of how impressive it sounds on the label. Delivery is the formulation's answer to that challenge.
This reframes where the advantage in active skincare sits. As named actives become widely available, the same ingredient appears across many products, and the delivery system becomes the difference between them. It is the practical expression of the wider shift from ingredient to mechanism, which we explore in our piece on mechanism over ingredient. For ingredients whose effect is known to depend heavily on delivery, such as the regenerative actives discussed in our article on PDRN in cosmetics, the delivery system is what makes a claim credible.
Why delivery, not the ingredient, often decides the result
The skin barrier exists to keep things out. That makes it a challenge for any active that is intended to work below the surface. An ingredient that cannot get past the barrier in a usable form does little, regardless of how impressive it sounds on the label. Delivery is the formulation's answer to that challenge.
This reframes where the advantage in active skincare sits. As named actives become widely available, the same ingredient appears across many products, and the delivery system becomes the difference between them. It is the practical expression of the wider shift from ingredient to mechanism, which we explore in our piece on mechanism over ingredient. For ingredients whose effect is known to depend heavily on delivery, such as the regenerative actives discussed in our article on PDRN in cosmetics, the delivery system is what makes a claim credible.
The market signals, framed as direction not guarantee
The signals here point to a direction of travel rather than a guaranteed result for any single product:
Ingredient saturation: as named actives become common, brands look to delivery as the difference between products that share the same ingredient.
Encapsulation interest: growing attention to encapsulated and carrier-based formats signals that delivery is becoming a recognised basis for differentiation.
Claim scrutiny: closer scrutiny of cosmetic claims favours formulations where the delivery system supports the stated effect rather than the ingredient name alone.
The practical reading: the opportunity is a product whose delivery system credibly supports its claim, not a label that names an active without the means to deliver it.
The formulation reality: the delivery system is part of the formulation
A delivery system is not something added to a formulation. It is part of how the formulation is built. Several factors decide whether an active is delivered in a usable way, and each is a formulation decision rather than an ingredient choice.
Factor | What it governs | Why it matters for the claim |
|---|---|---|
Encapsulation | Protection and controlled release of the active | Keeps the active stable and supports its intended action |
Fragment / molecule size | Whether the active can reach its target | An active too large to penetrate stays on the surface |
Carrier system | How the active moves through the formulation and onto the skin | Determines whether the active is presented in a usable form |
Stability | Whether the active survives in the product | An unstable active degrades before it can act |
Because effect is formulation-dependent on these decisions, a delivery system cannot be bought as an ingredient and added in. It has to be designed and tested within the formulation. This is exactly why in-house development matters: encapsulation, carrier and stability have to be built into the base and validated on a real product.
Positioning a delivery-led product so the claim is credible
Delivery is a strong story, but it has to be told accurately. Three angles tend to hold up:
Delivery as the differentiator: explaining that the product is built to deliver its active, not only to contain it, is a durable story that a shared ingredient name cannot match.
Claim tied to delivery: the claim should describe the cosmetic effect that the delivery system supports, rather than borrow a clinical promise the formulation cannot back.
Honest about limits: framing penetration in terms of reaching where the active is intended to work, within cosmetic limits, avoids implying a medical or systemic effect.
Claims should stay cosmetic. A delivery system supports how an active performs on and in the upper skin within cosmetic limits. It does not deliver a drug or a medical effect, and the framing should make that clear.
How Labtree builds and tests a delivery system
The difficulty with a delivery system is that it cannot be sourced. An active can be ordered, but encapsulation, carrier and stability have to be designed into the formulation and proven on a real product. That requires a real lab, not only access to ingredients.
At Labtree, development happens in our own lab from a real formulation base. That makes it possible to build a product around its delivery system rather than only around the active: encapsulation, carrier and stability can be specifically developed, tested and adapted, and smaller test batches can be produced in-house to validate the delivery and stability early under real conditions. This is the first differentiator in practice: development on a real formulation base instead of development into the unknown. It is also where a development partner that builds its own formulations differs structurally from a sourcing platform that brokers materials.
Physical samples of pre-qualified formulations ship within 24 hours from the sample warehouse, free of charge for standard samples, so the texture and feel of the delivery-led product can be assessed on a real product rather than in theory. That early physical evidence reduces development loops.
The 5-phase process applied to a delivery-led product
Conception: defining the active, the delivery approach (encapsulation, carrier) and the cosmetic effect it should support, and matching them to a suitable base from the Labtree pool.
Sampling: standard samples of pre-qualified formulations within 24 hours for a first read on texture and feel of the delivery-led product.
Individualisation: developing and adjusting the delivery system, balancing encapsulation, carrier and stability with the sensory profile, iterating with further samples.
Prototyping: a production-near test batch, with stability central. Packaging, design, regulatory requirements and production capability are considered early and in parallel with formulation development, rather than addressed only after final formulation approval.
Production: scaling to the initial batch and into routine production, coordinated because production capability was considered during prototyping.
Real in-house development: a delivery system has to be designed and tested, not sourced, so an own lab is essential rather than ingredient access alone.
Own formulation base: a real base to build the delivery system into, rather than starting every project from a blank page.
Stability capability: the ability to test and validate stability in-house, since an unstable active fails regardless of its delivery.
Sampling speed: samples within 24 hours is a realistic benchmark, and free standard shipping is a meaningful signal.
Claim discipline: a partner who keeps the claim tied to what the delivery system supports, within cosmetic limits, protects the brand from over-claiming.
An active is only as good as its delivery. Encapsulation, fragment or molecule size, carrier and stability decide whether an ingredient reaches where it is intended to work, and therefore whether a claim is credible. As named actives become common, the delivery system is increasingly what sets one product apart from another. Because a delivery system has to be designed and tested in a lab rather than sourced as an ingredient, in-house development on a real formulation base, with stability validation and early physical samples, turns a delivery-led concept into a structured, plannable project rather than a leap into the unknown.
Weitere nützliche Links
FAQ
Does Labtree have its own laboratory?
Yes. Labtree has its own development competence including a laboratory. This means formulations are not only selected but specifically developed, tested and adapted. In addition, smaller test batches can be produced in-house to validate products early under real conditions and move them safely into production.
What is a delivery system in skincare?
A delivery system is how a formulation carries an active to where it is intended to work, using encapsulation, carriers and the management of fragment or molecule size. It determines whether an ingredient reaches its target in a usable form. Because the same active can perform very differently depending on delivery, the delivery system is part of what makes a claim credible.
Why can two products with the same active perform differently?
Because the delivery system differs. One product may carry the active to where it is intended to work and keep it stable, while the other leaves it on the surface or lets it degrade. The active is the same on the label, but the result is formulation-dependent, which is why delivery often decides the outcome.
Can a delivery system simply be added to a formula?
No. Encapsulation, carrier and stability have to be designed into the formulation and proven on a real product, not ordered as an ingredient. That requires in-house development rather than ingredient access alone, which is why an own lab matters for a delivery-led product.
How long does it take to develop a delivery-led product?
With a pre-qualified base as a starting point, a white-label route is typically 2 to 3 months. An individual new development is usually 3 to 6 months, depending on the complexity of the delivery system, stability testing, regulatory preparation and packaging availability.
What can a delivery system claim within cosmetic limits?
A delivery system supports how an active performs on and in the upper skin within cosmetic limits. It does not deliver a drug or produce a medical or systemic effect, and the claim should make that clear. Because development happens in our own lab, the delivery and its cosmetic effect are documented together, which keeps the claim close to what the formulation supports.
Jetzt weitere Artikel entdecken
